PW Medtech Group Ltd. ( (HK:1358) ) has issued an update.
Sichuan Ruijian Medical, a subsidiary of PW Medtech Group Ltd., reported a significant revenue increase of 43.89% in the first quarter of 2025 compared to the previous year, driven by market expansion and increased brand awareness. The company is also progressing towards a public stock issuance and listing on the Beijing Stock Exchange, indicating growth and potential new opportunities for stakeholders.
More about PW Medtech Group Ltd.
PW Medtech Group Ltd. is an investment holding company incorporated in the Cayman Islands, primarily engaged in the research and development, manufacturing, and sales of advanced infusion sets, intravenous cannula products, insulin needles, blood purification medical devices, and regenerative medical biomaterials in China. Its subsidiary, Sichuan Ruijian Medical, focuses on medical devices for blood purification.
YTD Price Performance: 8.18%
Average Trading Volume: 4,453
Technical Sentiment Signal: Strong Sell
Current Market Cap: €171.5M
For detailed information about 1358 stock, go to TipRanks’ Stock Analysis page.